- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trialsThe GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety pro…Endpoints · 17d ago↗ source
- Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first halfBiopharma's M&A engine is revved up and shows no signs of cooling off. Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $1…Endpoints · 17d ago↗ source
- MeiraGTx strikes royalty deal; Fore's 2023 Series D continuesPlus, news about Kalohexis, Teva and Agios: 👑 MeiraGTx makes royalty deal with Oberland Capital: The gene therapy maker will get an initial $135 million via a $10 million equity investment ...